{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:23:47Z","timestamp":1787559827906,"version":"build-2736575974"},"reference-count":46,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder that significantly impairs patients\u2019 quality of life. Antispasmodics such as mebeverine and otilonium bromide (OB) are commonly used as first-line therapies; however, comparative evidence regarding their effectiveness and safety profile remains limited. This study aimed to compare short-term changes in health-related quality of life and the occurrence of adverse events among IBS patients receiving mebeverine or otilonium bromide. A prospective cohort study was conducted from December 2024 to July 2025 among 110 IBS patients meeting the Rome IV criteria who received either mebeverine 200 mg or OB 40 mg twice daily for 4 weeks. The IBS-specific quality-of-life questionnaire (IBS-QOL) was interviewer-administered at baseline and after treatment (week 4). Adverse drug events were documented and classified according to the Common Terminology Criteria for Adverse Events (CTCAE). After 4 weeks, significant within-group improvements in the overall IBS-QOL score and most domain scores were observed in both treatment groups. In the unadjusted between-group analysis, the mean improvement in the overall IBS-QOL score was greater in the mebeverine group than in the otilonium bromide group (20.31 \u00b1 13.17 vs. 14.62 \u00b1 14.61; p = 0.034). However, treatment group was not independently associated with change in the overall IBS-QOL score after multivariable adjustment (OB vs. mebeverine: B = \u22124.63, 95% CI \u221210.28 to 1.02; p = 0.107). Nominal differences in activity interference and health worry did not remain statistically significant after Holm correction for multiple domain-level comparisons. Adverse events occurred in 9 of 110 patients (8.2%), with no significant difference between the mebeverine and otilonium bromide groups (11.7% vs. 4.0%; Fisher\u2019s exact p = 0.178). All reported events were mild. In this prospective observational cohort, both mebeverine and otilonium bromide use was associated with short-term improvement in health-related quality of life and low rates of mild adverse events. Although the unadjusted change in the overall IBS-QOL score favored mebeverine, the adjusted analysis did not establish an independent difference between the two treatments.<\/jats:p>","DOI":"10.3390\/life16091390","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:03:41Z","timestamp":1787558621000},"page":"1390","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Mebeverine and Otilonium Bromide on Health-Related Quality of Life in Patients with Irritable Bowel Syndrome: A Prospective Cohort Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8179-5418","authenticated-orcid":false,"given":"Anh Thi Phuong","family":"Luu","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 72714, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-7861","authenticated-orcid":false,"given":"Thong Duy","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 72714, Vietnam"},{"name":"Department of Gastroenterology, University Medical Center Ho Chi Minh City, Ho Chi Minh City 72714, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","unstructured":"Patel, N., and Shackelford, K.B. (2025, July 17). Irritable Bowel Syndrome, StatPearls [Internet], Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534810\/."},{"key":"ref_2","unstructured":"(2025, August 04). Rome IV Criteria\u2014Rome Foundation [Internet]. Available online: https:\/\/theromefoundation.org\/rome-iv\/rome-iv-criteria\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.21037\/atm-21-2779","article-title":"Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: A narrative review","volume":"9","author":"Tang","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Stoyanova, M., Gledacheva, V., and Nikolova, S. (2025). Gut\u2013Brain\u2013Microbiota Axis in Irritable Bowel Syndrome: A Narrative Review of Pathophysiology and Current Approaches. Appl. Sci., 15.","DOI":"10.3390\/app15126441"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nguyen, Q.H., Lam, H.T., Trinh, T.T.T., and Vo, T.D. (2026). Clinical Features and Symptom Burden in Vietnamese Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Single-Center Cross-Sectional Study Using IBS-SSS and IBS-QoL Scores. J. Clin. Med., 15.","DOI":"10.3390\/jcm15082910"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1705376","DOI":"10.3389\/fmed.2026.1705376","article-title":"Exploring IBS in Vietnam: An updated review of current trends and treatment landscape","volume":"13","author":"Vo","year":"2026","journal-title":"Front Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jgh3.12477","article-title":"Effectiveness of educational intervention carried out by clinical pharmacists for the quality of life of patients with irritable bowel syndrome: A randomized controlled trial","volume":"5","author":"Thong","year":"2020","journal-title":"JGH Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1572-0241.2003.04023.x","article-title":"Clinical patterns over time in irritable bowel syndrome: Symptom instability and severity variability","volume":"99","author":"Mearin","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1572-0241.2007.01740.x","article-title":"Irritable bowel syndrome: A 10-yr natural history of symptoms and factors that influence consultation behavior","volume":"103","author":"Ford","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/gast.2000.16484","article-title":"The impact of irritable bowel syndrome on health-related quality of life","volume":"119","author":"Gralnek","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1477-7525-11-208","article-title":"Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients","volume":"11","author":"Andrae","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG Clinical Guideline: Management of Irritable Bowel Syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5056\/jnm25007","article-title":"2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome","volume":"31","author":"Choi","year":"2025","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.gastro.2022.04.016","article-title":"AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Constipation","volume":"163","author":"Chang","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_17","first-page":"105","article-title":"Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome","volume":"23","author":"Rahman","year":"2014","journal-title":"Mymensingh Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.15419\/bmrat.v5i10.493","article-title":"Efficacy of adding Luvos\u00ae Healing Earth supplementation to mebeverine in improving symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial","volume":"5","author":"Mokhtare","year":"2018","journal-title":"Biomed. Res. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2982.2011.01771.x","article-title":"Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine","volume":"23","author":"Lee","year":"2011","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jep.2013.05.034","article-title":"Treatment of irritable bowel syndrome using a selected herbal combination of Iraqi folk medicines","volume":"148","author":"Sahib","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.gastro.2025.02.030","article-title":"Mebeverine and the Influence of Labeling in Adolescents with Irritable Bowel Syndrome or Functional Abdominal Pain Not Otherwise Specified: A 2 \u00d7 2 Randomized, Placebo-Controlled Trial","volume":"169","author":"Rexwinkel","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3748\/wjg.v16.i5.547","article-title":"A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome","volume":"16","author":"Nikfar","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1742-1241.2000.tb10900.x","article-title":"Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome","volume":"54","author":"Gilbody","year":"2000","journal-title":"Int. J. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2174\/1381612824666180507122935","article-title":"Otilonium Bromide: A Drug with a Complex Mechanism of Action","volume":"24","author":"Evangelista","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/phrs.1998.0340","article-title":"Receptor binding profile of Otilonium bromide","volume":"38","author":"Evangelista","year":"1998","journal-title":"Pharmacol. Res."},{"key":"ref_26","first-page":"5","article-title":"Autoradiographic localization of octylonium bromide binding sites in the rat gastrointestinal tract","volume":"311","author":"Amenta","year":"1991","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/sj.bjp.0704942","article-title":"The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts","volume":"137","author":"Lindqvist","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.14309\/00000434-201410002-01824","article-title":"Effect of Otilonium Bromide in the Treatment of Irritable Bowel Syndrome: A Meta-Analysis: 1824","volume":"109","author":"Ahmad","year":"2014","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.3748\/wjg.v20.i34.12283","article-title":"Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial","volume":"20","author":"Reggiardo","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_30","unstructured":"National Cancer Institute, and U.S. Department of Health and Human Services (2025, September 15). ComCommon Terminology Criteria for Adverse Events (CTCAE), Version 5.0, Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40261-014-0233-y","article-title":"Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study in Poland, Egypt, Mexico and China","volume":"34","author":"Hou","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Daniluk, J., Malecka-Wojciesko, E., Skrzydlo-Radomanska, B., and Rydzewska, G. (2022). The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041044"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/pubmed\/fdi031","article-title":"Mode of questionnaire administration can have serious effects on data quality","volume":"27","author":"Bowling","year":"2005","journal-title":"J. Public Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"21514593251331539","DOI":"10.1177\/21514593251331539","article-title":"Does Patient Health Literacy Affect Patient Reported Outcome Measure Completion Method in Orthopaedic Patients?","volume":"16","author":"Trotter","year":"2025","journal-title":"Geriatr. Orthop. Surg. Rehabil."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ueg2.12277","article-title":"Irritable bowel syndrome: Factors of importance for disease-specific quality of life","volume":"10","author":"Melchior","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e14756","DOI":"10.1111\/nmo.14756","article-title":"Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden","volume":"36","author":"Khasawneh","year":"2024","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.14309\/01.ajg.0000858920.87360.27","article-title":"Comparison of Quality of Life Between Patients with Diarrhea- and Constipation-Predominant Irritable Bowel Syndrome","volume":"117","author":"BouSaba","year":"2022","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2036.2011.04730.x","article-title":"Randomised clinical trial: Otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome","volume":"34","author":"Acalovschi","year":"2011","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1756283X16681708","article-title":"Efficacy of otilonium bromide in irritable bowel syndrome: A pooled analysis","volume":"10","author":"Tack","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5056\/jnm.2011.17.4.402","article-title":"The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome","volume":"17","author":"Chang","year":"2011","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/CEG.S46291","article-title":"Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: A literature review","volume":"7","author":"Triantafillidis","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_42","first-page":"22","article-title":"Sulpiride treatment of irritable colon syndrome","volume":"78","author":"Komarov","year":"2000","journal-title":"Klin. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.22270\/jddt.v9i5.3424","article-title":"New regimen for treatment of irritable bowel syndrome with emphasis on Sulpride as the sole maintenance therapy","volume":"9","year":"2019","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_44","unstructured":"Vo, D.T., and Nguyen, N.P. (2021). The Effect of Sulpiride in Improving Quality of Life of Patients with Irritable Bowel Syndrome. Vietnam Med. J., 502."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/106002809502900210","article-title":"Sulpiride: An antipsychotic with selective dopaminergic antagonist properties","volume":"29","author":"Caley","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/BF00607085","article-title":"Inhibition of postprandial colonic motility by sulpiride in patients with irritable colon","volume":"24","author":"Lanfranchi","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:17:51Z","timestamp":1787559471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["life16091390"],"URL":"https:\/\/doi.org\/10.3390\/life16091390","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}